Three Companies Received Orphan Drug Designations in One Day To Treat Rare Cancers
The FDA posted three new Orphan Drug Designations (ODD) on June 17 for two companies targeting brain cancer, Kazia and VBI, and one company targeting a type of liver cancer, Hepion. An orphan drug is a treatment targeting a disease that affects less than 200,000 people in the United States. All three companies will use the ODD and the associated benefits to further the development of their drugs targeting rare cancers.
It's free! Log in now to read